Overlap of Gestational Diabetes Mellitus and Pre-eclampsia: A Scoping Review Authors: Lunghar Janeline, Thyparambil Aravindakshan PramodKumar, Mohan Deepa, Balaji Bhavadharini, Uddhav Chaudhari, Geetanjali Sachdeva, Sadhana Joshi, Haritha Sagili, Anish Keepanasseril, Sadish Kumar Kamalanathan, Polina Popova, Ponnusamy Saravanan, Uma Ram, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Viswanathan Mohan Published: 2026 ABSTRACT AbstractGestational diabetes mellitus (GDM) and preeclampsia (PE) are among the most common medical complications in pregnancy, with prevalence rates of 10–25% and 3–9.4%, respectively. Both conditions are important causes of maternal and neonatal morbidity and pose considerable risks to maternal and fetal health. GDM and PE are traditionally viewed as distinct clinical entities. However, they share several common risk factors, including advanced maternal age, obesity, family history of metabolic disease, dyslipidemia and genetic predisposition. The two conditions also have overlapping pathophysiological pathways, particularly involving metabolic and vascular dysfunctions such as insulin resistance, chronic inflammation and endothelial dysfunction. This article reviews the prevalence of GDM and PE, the risk factors common to the two conditions and biomarkers that may aid in early identification of these disorders. The report also discusses clinical implications of the overlap between the two disorders, with a plea for integrated management strategies. Finally, the article also highlights potential preventive measures and underscores the importance of multidisciplinary approaches to improve pregnancy outcomes in those with GDM and PE.Keywords: Gestational diabetes mellitus, Preeclampsia, Epidemiological association, Risk factors pathophysiology overlap, Biomarkers Key Summary Points Gestational diabetes mellitus (GDM) and preeclampsia (PE) are prevalent complications of pregnancy that are traditionally examined independently; however, emerging evidence indicates significant clinical and biological overlap between the two conditions.This review critically synthesizes evidence on the shared pathophysiological pathways, including metabolic dysregulation, endothelial dysfunction and inflammatory processes, as well as potential biomarkers that may explain co-occurrence of GDM and PE.The identification of one condition may signal an elevated risk for the other, highlighting the need for more integrated clinical surveillance and risk assessment during pregnancy.Because the coexistence of GDM and PE is associated with compounded maternal and fetal risks, improved strategies for early detection, risk stratification and coordinated management are essential to reduce adverse pregnancy outcomes.More research is needed on the pathophysiology and mechanisms to explore the overlap of GDM and PE. Introduction Gestational diabetes mellitus (GDM) refers to glucose intolerance first identified during pregnancy [1, 2], whereas preeclampsia (PE) is characterized by new-onset hypertension with proteinuria or end-organ dysfunction, typically manifesting after 20 weeks of gestation [3]. GDM and PE are among the most prevalent metabolic and vascular complications of pregnancy, collectively affecting a substantial proportion of pregnancies worldwide [4]. The prevalence of GDM varies from 10% to 25% [5] of all pregnancies, with particularly high and rising rates in South Asian, Southeast Asian and Middle Eastern populations (even > 30%), while hypertensive disorders of pregnancy, including PE, affect 3–9.4% of pregnancies globally [2, 6, 7]. Together, these conditions contribute significantly to maternal and perinatal morbidity and mortality and represent major public health concerns. Although traditionally considered distinct entities and managed separately, accumulating evidence indicates substantial overlap in their pathophysiology, risk factors and downstream consequences. Shared mechanisms such as insulin resistance, endothelial dysfunction, placental insufficiency, inflammation and dyslipidemia suggest convergent metabolic-vascular pathways underlying both conditions. Beyond immediate perinatal outcomes, adverse intrapartum events and altered fetal growth trajectories in GDM and PE have important long-term implications for both the mother and the offspring, underscoring a shared cardiometabolic continuum. Women with a history of GDM or hypertensive disorders of pregnancy are at markedly increased risk of future type 2 diabetes (T2D), hypertension and cardiovascular disease (CVD), while their offspring exhibit higher lifetime susceptibility to obesity, insulin resistance, T2D, hypertension and premature CVD, likely mediated through fetal programming. While large-for-gestational-age (LGA) babies are typical of GDM, an unresolved conundrum within this framework is the occurrence of small-for-gestational-age (SGA) infants in some pregnancies complicated by GDM. While SGA is traditionally reported in approximately 5–7% of GDM pregnancies [8, 9], emerging data suggest a substantially higher prevalence among Indian women with GDM, indicating population-specific metabolic, nutritional and placental factors. The coexistence of PE further modifies this risk: early-onset PE is strongly associated with placental dysfunction, SGA and preterm birth, whereas in late-onset PE, SGA is comparatively less prominent. This review examines possible overlap between GDM and PE and calls for awareness of their coexistence, thereby helping the institution of appropriate treatment for both conditions with the following objectives: To comprehensively synthesize current evidence on the prevalence, shared risk factors, pathophysiological mechanisms and biomarkers contributing to the coexistence of GDM and PE To comprehensively synthesize current evidence on the prevalence, shared risk factors, pathophysiological mechanisms and biomarkers contributing to the coexistence of GDM and PE To identify gaps in evidence and outline future research directions along with integrated prevention and management strategies aimed at improving maternal and neonatal outcomes To identify gaps in evidence and outline future research directions along with integrated prevention and management strategies aimed at improving maternal and neonatal outcomes Methodology Literature Search Strategy We examined epidemiological studies reporting the prevalence and risk factors for overlap between gestational diabetes mellitus (GDM) and preeclampsia (PE). A comprehensive and structured literature search was conducted across PubMed, Scopus and Web of Science using database-specific search strategies. In PubMed, the search strategy used Medical Subject Headings (MeSH) and relevant free-text keywords to enhance search sensitivity and precision. The primary MeSH terms used were “Diabetes, Gestational” [MeSH] and “Pre-Eclampsia” [MeSH], combined using the Boolean operator AND. Additional synonyms and related terms were included to avoid omitting studies that were not yet MeSH-indexed. PubMed search strategy: (“Diabetes, Gestational” [MeSH] OR gestational diabetes mellitus OR GDM OR hyperglycaemia in pregnancy) AND (“Pre-Eclampsia” [MeSH] OR preeclampsia OR pre-eclampsia OR gestational hypertension OR hypertensive disorders of pregnancy). Since Scopus and Web of Science do not use MeSH indexing, equivalent free-text searches were conducted across the title, abstract and keyword fields. Scopus search strategy: TITLE-ABS-KEY (gestational diabetes mellitus OR GDM OR hyperglycaemia in pregnancy) AND TITLE-ABS-KEY (preeclampsia OR pre-eclampsia OR gestational hypertension OR hypertensive disorders of pregnancy) Web of Science search strategy: TS = (gestational diabetes mellitus OR GDM OR hyperglycaemia in pregnancy) AND TS = (preeclampsia OR pre-eclampsia OR gestational hypertension OR hypertensive disorders of pregnancy). Consequently, in addition to database searches, manual screening of reference lists of included studies and relevant reviews was performed to identify additional eligible studies not captured through electronic searches because of indexing limitations or variability in terminology. These supplementary search strategies were used to ensure comprehensive coverage using key terms such as gestational diabetes mellitus, preeclampsia, hypertension in pregnancy and hyperglycemia in pregnancy, and manual screening of key obstetrics and endocrinology journals was performed. Study Screening, Selection, Data Charting and Synthesis A total of 1433 records were retrieved from the database search and subsequently imported into the Rayyan platform to support a transparent and systematic screening procedure. Independent screening was performed by two reviewers, yielding a high level of concordance (98%). Twenty-seven discrepancies were identified and resolved through discussion, with involvement of a third reviewer when required. Of the 1433 records identified, 83 duplicates were removed, and we obtained 1350 articles. During title and abstract screening, we found nonrelevant articles, inappropriate study design (n = 1312) and insufficient data/unsuitable data (n = 23), resulting in 15 studies being included. While the inclusion rate appears low, this reflects the deliberately broad search strategy employed to maximize sensitivity and ensure comprehensive capture of all potentially relevant studies on GDM and PE. The large number of exclusions primarily arose because of the specificity of our eligibility criteria. In particular, many studies examined GDM or PE independently rather than their co-occurrence, focused on mechanistic or biomarker-based outcomes without epidemiological data, or did not report both conditions within the same population. Additionally, non-original articles (e.g., editorials, reviews, case reports, commentaries), studies with small sample sizes, studies involving non-relevant populations (e.g., type 1 or type 2 diabetes) and studies not designed to assess the association between GDM and PE were excluded. For methodological transparency, systematic reviews and meta-analyses were excluded from the scoping review dataset, as they do not constitute primary studies. However, they were cited in the discussion section as contextual background literature to aid in the interpretation of findings from the included primary studies and were not part of the 15 studies analyzed within the scoping review dataset. In addition to the database searching, manual hand-searching was also performed. Notably, all studies identified through hand-searching were subjected to the same predefined inclusion and exclusion criteria as those identified through database searches, minimizing the risk of selection bias. In addition, eligibility was limited to English-language publications from 2015 to 2025 and included epidemiological and observational research designs, including randomized clinical trials, cross-sectional studies and prospective cohort studies. After duplicate removal and preliminary screening, many records were excluded at the title and abstract stage because of insufficient relevance to the study objective. Exclusion criteria comprised studies that: (1) evaluated GDM or PE in isolation without examining their relationship; (2) focused solely on biomarkers or experimental outcomes without epidemiological context; (3) represented non-original literature such as editorials, commentaries or narrative reviews; (4) involved small samples (n < 30) or case reports; and (5) included populations not pertinent to the research question, such as individuals with type 1 or type 2 diabetes. Studies with < 30 participants were excluded to ensure adequate statistical reliability and reduce the influence of small-sample bias. Very small studies often produce unstable estimates with wide confidence intervals and may not adequately represent the target population. Therefore, restricting inclusion to studies with > 30 participants helped improve the methodological robustness and comparability of the evidence synthesized in this review. The overall selection pathway is illustrated in the PRISMA flow diagram (Fig. 1). Process adopted for selection of studies included in this paper Following study inclusion, a structured data charting tool was developed a priori to enable standardized extraction of study characteristics. Extracted variables included prevalence rate, association between GDM and PE, risk factors, maternal and neonatal outcomes, and other non-variables like study setting, sample size, study design and diagnostic criteria for GDM and PE; measures of association between the two conditions and methodological limitations were captured. Following this, data extraction was performed in duplicate by two reviewers using the standardized charting template. The extracted data were subsequently cross-checked for accuracy and completeness. Any discrepancies between reviewers were resolved through discussion and consensus. This process was implemented to minimize extraction errors and ensure the reliability of the charted information. The extracted information was subsequently organized and synthesized using a thematic approach to comprehensively map the existing evidence. Key analytical domains guiding the narrative synthesis included: (1) epidemiological associations between GDM and PE, (2) shared pathophysiological pathways, (3) variability in diagnostic definitions, (4) geographical differences in reported relationships and (5) maternal and neonatal complications associated with concurrent GDM and PE. These domains informed the structure of the Results and Discussion sections. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required. Results and Discussion The database search yielded 1433 records, with an additional 32 records identified through hand searching. After removal of duplicates and screening, a total of 15 studies met the inclusion criteria and were included in the final review. The study selection process is presented in the PRISMA flow diagram (Fig. 1). Prevalence of GDM and PE The prevalence of GDM is increasing across all populations, with advancing maternal age and obesity consistently associated with higher risk, irrespective of income level or geographic region. According to the International Diabetes Federation (IDF) Diabetes Atlas, 11th edition, 2025 [2], the global prevalence of hyperglycemia in pregnancy is 19.7%, with Africa having the lowest age-standardized prevalence (13.8%) and Southeast Asia the highest (31.7%). This heterogeneity in GDM prevalence rates reflects differences in screening strategies, diagnostic criteria, population characteristics and access to healthcare services. To highlight this point, if we look at variation in GDM diagnostic criteria, several criteria, e.g., IADPSG, DIPSI, WHO 1999 and Carpenter & Coustan, were used, as shown in Table 1. This is apart from the wide variation in sample sizes, ranging from small clinical cohorts to national population datasets, geographic diversity across multiple regions, differences in study design and population characteristics. Despite multiple international guidelines, controversy persists regarding both the optimal diagnostic thresholds for GDM and the most appropriate glycemic targets for management. Variations in oral glucose tolerance test (OGTT) protocols (50 g, 75 g, 100 g loads; 2‐ vs. 3‐h measurements), fasting vs non-fasting OGTTs and differing cutoff values continue to impede global consensus on GDM diagnosis and treatment goals [10]. The impact of diagnostic criteria on the prevalence estimates is well illustrated by data from India, in which GDM prevalence was reported as 18.5% using the IADPSG criteria and 14.6% using the WHO 1999 criteria [5]. In addition, studies also vary widely in design and sample size, ranging from modest single-center ones to large national surveys, such as the study by Swaminathan et al. [11], which included over 32,000 participants [6]. According to the latest findings from the ICMR-INDIAB study, the national prevalence of GDM in India is 22.4% [12]. Table 1Prevalence of gestational diabetes mellitus and preeclampsia with key findings in various studiesReferences and yearStudy populationsCriteria for GDMTime of screeningSample sizeSettingsGDM prevalence %PE prevalence %GDM and PE associated riskKey findingsCheung et al. [15] 2018AustraliaIADPSGNot reported375Not specified2.04.0YesMaternal obesity and hyperglycemia increased risk of hypertensive complications and adverse neonatal outcomesJayawardane et al. [16] 2018SrilankaNot specifiedNot reported782Hospital basedNot specifiedNot specifiedYesEarly hyperglycemia associated with increased neonatal complicationsKosir Pogacnik et al. [17] 2020IsraelIADPSGNot reported226,676Not specified1.82.1YesLarge population study confirming increased PE risk among women with GDMWeschenfelder et al. [18] 2020EthiopiaNot specifiedNot reportedNot specifiedNot specifiedNot specifiedNot specifiedYesIdentified predictors linking metabolic and hypertensive pregnancy disordersChebrolu et al. [19] 2021IndiaDIPSI24–28 weeks575Hospital based rural1.9Not specifiedYesGDM associated with increased hypertensive disordersKivelä et al. [20] 2021FinlandFinnish clinical guidelines < 20 weeks741Hospital based27.97YesEarly GDM diagnosis associated with increased hypertensive complicationsSaei Ghare Naz et al. [21] 2022IranNot specifiedNot reported2820Hospital basedNot specifiedNot specifiedYesAssociation observed between metabolic and hypertensive disordersKek et al. [22] 2023TaiwanNot specifiedNot reported2,297,613Cohort study TNHIRDNot specifiedNot specifiedYesLarge cohort demonstrating long-term cardiometabolic riskChatzakis et al. [23] 2023GreeceIADPSGNot reported6928Hospital setting3023.9YesCombined metabolic phenotype associated with hypertensive complicationsKumar et al. [24] 2023IndiaDIPSI < 20 weeks2050Antenatal clinic15.430.3YesPre-eclamptic women showed increased preterm birthsAziz et al. [25] 2024Saudi ArabiaIADPSGNot reported140Hospital based0.80.71YesMetabolic syndrome components linked to PE developmentNicolì et al. [105] 2025Italy–20 weeks389Hospital based53.58 HDPYesHigh GDM prevalence associated with hypertensive disordersHiware et al. [106] 2025IndiaCarpenter and Coustan24–28 weeks248Hospital based25.8YesObserved coexistence of GDM and PEYe et al. [107] 2025ChinaIADPSG24–28 weeks212Hospital basedPE in GDM 28.3YesHigh PE incidence among women with GDMDomaracki et al. [31] 2026PolandGHDC> 20 weeks207Hospital basedGH = 2–7YesGestational hypertension associated with metabolic disturbancesGDM gestational diabetes mellitus, PE preeclampsia, HDP hypertension disorder of pregnancy, GH gestational hypertensive, TNHIRD Taiwan National Health Insurance Research Database, DIPSI Diabetes in Pregnancy study group of India, IADPSG International Association of Diabetes and Pregnancy study groups; Associated prevalence percentage of GDM (Gestational Diabetes Mellitus) and PE (Preeclampsia), SNNPR Southern Nations, Nationalities and Peoples’ Region, ICD International Classification of Diseases, ADA American Diabetes Association, NDDG National Diabetes Data Group, ADIPS Australasian Diabetes in Pregnancy Society, WHO World Health Organization 1999, GHDC gestation hypertension diagnostic criteria Prevalence of gestational diabetes mellitus and preeclampsia with key findings in various studies GDM gestational diabetes mellitus, PE preeclampsia, HDP hypertension disorder of pregnancy, GH gestational hypertensive, TNHIRD Taiwan National Health Insurance Research Database, DIPSI Diabetes in Pregnancy study group of India, IADPSG International Association of Diabetes and Pregnancy study groups; Associated prevalence percentage of GDM (Gestational Diabetes Mellitus) and PE (Preeclampsia), SNNPR Southern Nations, Nationalities and Peoples’ Region, ICD International Classification of Diseases, ADA American Diabetes Association, NDDG National Diabetes Data Group, ADIPS Australasian Diabetes in Pregnancy Society, WHO World Health Organization 1999, GHDC gestation hypertension diagnostic criteria Preeclampsia affects approximately 2–10% of pregnancies globally. Prevalence of PE is notably higher in developing countries, where it ranges from 1.8% to 16.7% [3, 13]. Across individual studies, prevalence of PE varies widely, ranging from 0.71% in Saudi Arabia to 24% in Greece [2, 14]. The prevalence of GDM and PE, as reported in various studies globally, shows their overlap. This table [5, 10–23] enumerates study-specific metrics, including reference, year, population (e.g., Australia, India, Israel), GDM diagnostic criteria (e.g., IADPSG, DIPSI, Finnish guidelines), screening timing (e.g., 24–28 weeks or < 20 weeks), sample sizes (ranging from 140 to 2,297,613), settings (hospital-based, cohort, antenatal clinics), GDM prevalence (0.8–53.5%), PE prevalence (0.71–30.3%) and confirmed GDM-PE associations (“Yes” in all cases). Notable variations include high GDM rates in Italy (53.5%) and Greece (30%), with Indian studies [19, 24] using DIPSI criteria reporting 1.9–15.4% GDM alongside elevated PE risks. Large cohorts in Taiwan [22] also underscore population-level links. Studies that did not report GDM or PE prevalence were marked as “not specified” and were still included because they examined the link between GDM and PE. Overall, it shows wide variation in reported GDM (0.8–53.5%) and PE prevalence (0.7–30.3%) across different populations, diagnostic criteria and settings; however, all studies consistently report a positive association between GDM and PE. Key findings reveal consistent overlaps: maternal obesity and hyperglycemia increase hypertensive risk [15]; early GDM diagnosis correlates with PE [20]; metabolic phenotypes predict complications [23]; predictors such as dyslipidemia are associated with PE progression [25]. All studies affirm heightened perinatal morbidity in comorbid GDM-PE. The overall synthesis indicates a consistent and clinically significant association between GDM and PE across diverse study settings. Despite variability in diagnostic criteria and study methodologies, a strong and consistent association exists between GDM and PE across diverse geographic regions, as revealed by a comprehensive systematic review [26]. This pattern underscores a global epidemiological trend, suggesting that the link between these two pregnancy complications is not confined to specific populations or healthcare settings but rather reflects a widespread and clinically significant relationship [27–29]. Therefore, beyond increasing awareness, future research should focus on clarifying the underlying pathophysiological mechanisms, identifying early predictive markers and evaluating targeted preventive and therapeutic strategies. Accordingly, this review also aims to highlight key research gaps and potential treatment approaches related to GDM-associated PE. Shared Risk Factors and Epidemiological Association of GDM and PE Multiple studies have consistently demonstrated an increased risk and prevalence of PE among women with gestational diabetes mellitus [25, 29, 30]. Recent studies have identified several risk factors shared between GDM and PE. Figure 2 depicts the individual as well as overlapping risk factors GDM and PE. These include advanced maternal age, family history of T2D, environmental factors, PCOS, genetic susceptibility, obesity and elevated body mass index (BMI) [26, 27, 31]. PE risk is elevated at both extremes of maternal age, i.e., among teenage and older pregnant women, like that observed for GDM. This increased vulnerability can be attributed to age-related metabolic alterations, reduced insulin sensitivity and increased vascular stiffness, which together contribute to adverse pregnancy outcomes. Overlapping risk factors of gestational diabetes mellitus and preeclampsia Obesity increases the risk of GDM approximately threefold and the risk of PE twofold, and the coexistence of obesity and GDM further amplifies PE risk [32, 33]. Some studies show that even women without obesity diagnosed with GDM exhibit an increased risk of PE, although the strength of this association was lower than that seen in women with obesity [23]. Despite these inconsistencies, the overall body of evidence supports an independent association between GDM and PE in singleton pregnancies [26–31]. For instance, prospective cohort studies and meta-analyses have shown that glycosylated hemoglobin (HbA1c) in early pregnancy is significantly associated with the risk of both GDM and PE [34–36]. Furthermore, a history of GDM during the first pregnancy increases the risk of PE in the second pregnancy [37]. Data collected from the Korea National Health Insurance Claims Database showed that among 150,794 women studied, women with PE alone in the first pregnancy had an increased risk of GDM in the subsequent pregnancy compared with women who had neither condition [38]. Importantly, recent evidence suggests that PE characteristics may differ when they co-occur with GDM. A prospective cohort study by Bettikher et al. [39] demonstrated that severe preeclampsia was less frequent in women with both GDM and PE (13%) than those with PE alone (59%, p = 0.0014). This finding indicates that the presence of GDM may modify the clinical presentation and severity of PE and that GDM may warrant closer surveillance for PE. This has implications for risk stratification and management strategies for both GDM and PE [29, 40]. Pathophysiological Overlap Between GDM and PE GDM and PE share pathogenic mechanisms driven by insulin resistance, leading to hyperinsulinemia, inflammation and vascular dysfunction [41]. Pregnancy hormones further impair insulin sensitivity in GDM, resulting in glucose intolerance and adverse outcomes, if uncontrolled [41, 42]. PE is fundamentally a disorder of abnormal placentation leading to placental hypoperfusion, with subsequent release of anti-angiogenic and inflammatory factors that cause widespread maternal endothelial dysfunction, vasospasm and end-organ injury; variation in the extent of this endothelial response may therefore influence disease severity [39, 43]. Blood glucose levels are generally normal unless coexistent GDM is present, and hyperglycemia is not a diagnostic criterion for PE. The pathophysiology of PE is complex and involves maternal, fetal and placental components. In early pregnancy, abnormal placental vascular development can lead to hypoperfusion, hypoxia and ischemia, particularly in women predisposed to vascular dysfunction. This process triggers the release of anti-angiogenic factors into the maternal bloodstream, contributing to systemic endothelial dysfunction, hypertension and organ damage [37, 39, 44]. Findings from the longitudinal REVAMP study revealed the potential of soluble endoglin (sEng) levels and sEng/placental growth factor (PlGF) ratio as a biomarker for early identification of women who are at increased risk of developing PE [45]. Similarly, soluble fms-like tyrosine kinase-1 (sFlt-1) levels were higher in women with GDM at 11–14 weeks of gestation than in women without GDM. Women with GDM also had lower placental PLGF and Flt-1 levels, suggesting impaired placental angiogenesis in GDM, which in turn can affect placental function [46]. Several observational studies and meta-analyses have reported an association between low maternal 25‐hydroxyvitamin D [25(OH)D] levels and an increased risk of GDM and PE. Vitamin D deficiency, defined as 25(OH)D < 20 ng/ml, may impair pancreatic β‐cell function and promote insulin resistance, thereby contributing to hyperglycemia in pregnancy [47]. In addition to its metabolic effects, vitamin D exerts immunomodulatory and anti‐inflammatory effects that support proper placental development and endothelial function. Vitamin D insufficiency has been associated with higher rates of hypertensive disorders and abnormal placentation characteristic of PE [48]. It has been demonstrated that a deficiency of vitamin D leads to increased oxidative stress via alterations in one-carbon metabolism, which influences the omega-6 pathway (pro-inflammatory) and contributes to endothelial dysfunction and inflammation in placentae of pregnancies complicated by PE [49, 50]. In addition to lower maternal vitamin D levels, lower magnesium levels during mid-pregnancy (at 18–22 weeks of gestation) are reported to be associated with an increased risk of PE, suggesting that maternal nutrients play a role in the etiology of PE [51, 52]. However, in a large Russian nested case-control study, maternal serum 25(OH)D levels measured in both the first and third trimesters showed no significant association with subsequent GDM [53]. Notably, nearly half of the participants in this cohort exhibited vitamin D deficiency in early pregnancy, with persistently suboptimal levels later in gestation. While randomized trials of vitamin D supplementation in pregnancy have yielded mixed results, maintaining adequate vitamin D status through safe sun exposure, dietary intake and supplementation when indicated remains a potentially important strategy for reducing the incidence of both GDM and PE. A key research question that emerges from these overlapping mechanisms is whether early-pregnancy integrated screening using angiogenic biomarkers, maternal nutrient status (vitamin D and magnesium) and insulin-resistance markers can improve prediction and prevention of co-occurring GDM and PE while also clarifying their shared pathophysiology. Inflammation and Oxidative Stress Endothelial dysfunction, a hallmark of PE, is also observed in women with GDM during and after pregnancy [54]. Inflammatory markers such as C-reactive protein (CRP) levels are reported to be elevated in women with PE from early pregnancy, i.e., 11–14 weeks of gestation [55]. CRP has been linked to elevated blood pressure early in pregnancy and is also associated with an increased risk of developing GDM. Elevated CRP levels in early pregnancy have been reported to predict the subsequent development of GDM, and multiple studies have demonstrated significantly higher CRP levels in women with GDM compared with normoglycemic pregnancies [56, 57]. Receiver-operating characteristic (ROC) analyses further support CRP as a predictive biomarker for GDM [58, 59]. At the molecular level, several complex mechanisms have been proposed to explain the relationship between CRP and GDM [59, 60]. A longitudinal study examining oxidative stress markers revealed that women with PE had higher malondialdehyde (MDA) levels at 16–20 and 26–30 weeks of gestation but lower superoxide dismutase (SOD) levels at 26–30 weeks and at delivery [61, 62]. In addition, women with GDM experience elevated oxidative stress, largely driven by excessive production of reactive oxygen species (ROS). This process contributes to the formation of advanced glycation end-products (AGEs), which impair vasodilation and vascular function [63]. Elevated AGEs further promote the progression of PE by increasing oxidative stress and inflammatory signaling, reinforcing the mechanistic overlap between these two conditions. ROS interfere with both glucose transporter type 4 (GLUT4) and insulin receptor substrate-1 (IRS-1), thereby inhibiting insulin-stimulated glucose absorption [64]. Moreover, ROS inhibits glycogen synthesis in the liver and muscle. TNF-α and other pro-inflammatory cytokines may also increase the production and activity of ROS precursors, such as NADPH oxidase 4 (NOX4), thereby leading to oxidative stress [63, 64]. Inflammation, oxidative stress and angiogenesis are regulated by long-chain polyunsaturated fatty acids (LCPUFAs), including omega-3 and omega-6 fatty acids [65]. Thus, alterations in inflammatory, oxidative stress and angiogenesis pathways in pregnancy complications such as PE and GDM are likely due to altered fatty acid metabolism. Women with PE had higher erythrocyte SFAs and omega-6/omega-3 fatty acid ratios at 11–14 weeks and 18–22 weeks of gestation, respectively. Women with PE also reported a higher delta-6 desaturase index and a lower delta-5 desaturase index than the non-PE group at 11–14 and 18–22 weeks of gestation [62]. Differential methylation of lipid metabolism genes, such as fatty acid desaturase 2, and its association with altered fatty acid metabolism in women with PE provide a molecular basis for the findings of impaired LCPUFA levels in women with PE [66]. SFA and alpha-linolenic acid (ALA) levels were reported to be higher, whereas total PUFAs, eicosapentaenoic acid (EPA), omega-6 fatty acids, linoleic acid (LA) and arachidonic acid (AA) were lower in women with GDM at 18–22 weeks of gestation [67]. Recent studies show that placental fatty acid metabolites involved in inflammation resolution (lower resolvins and higher lipoxins) and fatty acid transporters (higher FATP1 and FATP4) are altered in women with GDM [67, 68]. Elevated maternal triglyceride levels have emerged as an important metabolic link between GDM and PE [69]. Pregnancy-related hypertriglyceridemia is exaggerated in GDM because of insulin resistance, leading to increased placental lipid transfer, oxidative stress and endothelial dysfunction, key pathways implicated in the pathogenesis of PE [54]. Higher triglyceride concentrations in early and mid-pregnancy have been independently associated with an increased risk of both GDM and PE, suggesting that dyslipidemia may represent a shared antecedent rather than a mere consequence of these disorders. These inflammatory and oxidative pathways establish the biological basis for the clinical overlap between GDM and PE. Clinically, these pathophysiological mechanisms manifest as increased risks of adverse outcomes, including preterm birth and intrauterine growth restriction [70]. Overall, it may be inferred that the risk of developing PE is higher in women with GDM. According to the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, the risk of developing PE increases with poor glycemic control, advanced maternal age, high BMI, short stature, unhealthy lifestyle habits, diabetes history and gestational age at the time of the oral glucose tolerance test (OGTT) [71]. Further studies should examine whether an increased risk of PE in women with GDM is analogous to increased risk of hypertension observed in those with diabetes in non-pregnant populations and further to elucidate the predictive role of early-pregnancy inflammatory and oxidative stress and lipid biomarkers in the progression from GDM to PE. Common Biochemical and Molecular Alterations in GDM and PE Polymorphisms in the genes related to insulin signaling and vascular function may also predispose women to both conditions [72]. Angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and miRNA146 rs2910164 (G/C) polymorphism have been associated with an increased incidence of PE in women with GDM [73]. Another study demonstrated shorter telomere length in women with GDM who developed PE compared with those who had GDM alone [74]. Therefore, genetic susceptibility, interacting with an altered cellular and molecular environment at the feto-maternal interface, may contribute to the progression from one pregnancy complication (GDM or PE) to the other. Several circulating proteins show similar patterns of alteration in both GDM and PE. Women with coexisting GDM and PE show elevated levels of visfatin, advanced oxidative protein products (AOPP) and fibroblast growth factor 21 (FGF21) [64, 75]. Placental growth factor (PLGF), well studied for its potential as a biomarker in PE, was significantly reduced in women with GDM in a retrospective cohort analysis [76]. Serum FGF21 levels in the early second trimester have been shown to correlate positively with the later development of GDM [75–77]. Oxidative stress-related markers, including AOPP, also correlate with concurrent GDM and PE; higher placental AOPP expression has been linked to greater disease severity [78–80]. Markers of glycemic variability, such as reduced levels of 1,5-anhydroglucitol (1,5-AG), may offer additional predictive value. A study conducted in South India reported significantly lower levels of 1,5-AG in women with GDM, suggesting its potential utility in identifying high-risk pregnancies [81]. Among angiogenic markers, the soluble Flt-1 (sFlt-1)/25 (OH)D ratio, one of the best markers of PE [82], has been proposed as a predictor of GDM [83]. sFlt-1, a soluble antagonist of VEGF, plays a central role in endothelial function, and its imbalance reflects angiogenic dysfunction. Elevated sFlt-1/25(OH)D ratios have been associated with a higher risk of adverse pregnancy outcomes, underscoring their potential clinical utility for predicting both PE and GDM [83]. However, more studies are needed on this to determine whether shared genetic polymorphisms and circulating biochemical biomarkers can reliably predict the progression and co-occurrence of GDM and PE. Placental Dysfunction A major factor in PE is dysfunctional placentation, which can also impact GDM, although the process is different. PE is primarily driven by abnormal trophoblast invasion and defective spiral artery remodeling early in pregnancy, leading to placental ischemia, oxidative stress and the release of anti-angiogenic factors (such as sFlt-1), which cause systemic maternal endothelial dysfunction. In GDM, by contrast, early hyperglycemia can affect placentation, but the mechanism is different. Hyperglycemia primarlily affects placental development through metabolic stress, inflammation, oxidative stress and altered nutrient sensing, rather than through primary failure of trophoblast invasion [84]. Hypertensive pregnancies are characterized by impaired placental development and function, resulting in inadequate uteroplacental blood flow. Oxidative stress, inflammation and the production of anti-angiogenic factors are the outcomes of this dysfunction, all of which worsen vascular function. In women with GDM and PE, insufficient remodeling of spiral arteries limits the flow of oxygen and nutrients, raising the risk of preterm birth, fetal development limitation and maternal problems [85–87]. Figure 3 depicts the pathophysiological overlap of GDM and PE. Whether hyperglycemia-induced placental metabolic stress disrupts spiral artery remodeling and angiogenic balance, thereby increasing susceptibility to PE, is an important research question that warrants further investigation. Pathophysiological flowchart for gestational diabetes mellitus and preeclampsia Clinical Implications of Overlap of GDM and PE The interlinked pathophysiology of PE and GDM has complex implications for maternal health, including the unmasking of pre-existing cardiovascular disease (CVD) predispositions. Both conditions are characterized by endothelial dysfunction, systemic inflammation, insulin resistance and adverse vascular remodeling, which may persist beyond pregnancy and contribute to long-term cardiovascular injury. Increasing evidence indicates that women with a history of PE or GDM have a substantially elevated lifetime risk of hypertension, ischemic heart disease, stroke and heart failure, independent of traditional risk factors [88]. These pregnancy complications may therefore act as early markers of accelerated cardiovascular aging. In this context, pregnancy is increasingly recognized as a ‘stress test’ that exposes latent cardiometabolic vulnerability, underscoring the importance of early cardiovascular risk stratification and long-term follow-up in affected women [89]. Importantly, both conditions share established risk factors that can be identified pre-pregnancy or early in pregnancy, providing opportunities for timely screening, diagnosis and intervention [90]. Polymorphisms in genes related to insulin signaling and vascular function may also predispose women to both conditions [72]. Elucidating the molecular interactions between GDM and PE could yield novel therapeutic targets. Integrative research focusing on shared biomarkers, epigenetics and precision medicine approaches will advance preventive and therapeutic strategies [90, 91]. Effective management of GDM (both early and late) is crucial for reducing maternal and neonatal morbidity, enhancing long-term quality of life and possibly reducing the occurrence of PE. Both GDM and PE are associated with long-term metabolic and cardiovascular complications if inadequately managed. Whether the combined exposure to GDM and PE accelerates long-term maternal cardiovascular risk and adverse cardiometabolic programming in offspring through shared vascular and metabolic mechanisms remains to be determined. Fortunately, several affordable and practical strategies can improve health outcomes in women with these conditions. These include maintaining optimal blood glucose levels through lifestyle modifications, (including dietary modifications and regular physical activity) and, when necessary, pharmacological treatment, as described below. Prevention of GDM and PE Lifestyle Modifications Dietary interventions and physical activity can reduce the risk of both GDM and PE. A balanced diet focusing on low-glycemic-index foods, adequate protein intake and regular physical activity has been shown to help regulate glucose levels and improve vascular function. Achieving and maintaining a healthy body weight, reducing sodium intake and increasing physical activity form the cornerstone of lifestyle management for both GDM and PE patients. According to Anjana et al. [92], recreational walking during pregnancy has been associated with better neonatal outcomes. In parallel, educational interventions are essential for empowering women with the knowledge and skills required for effective self-management. This includes improving the understanding of GDM and PE, adherence to prescribed treatment plans, self-care techniques and regular monitoring. Pharmacological Interventions Metformin and insulin are standard options for GDM management, and metformin also has vascular-protective effects that may reduce PE risk [93]. Labetalol and nifedipine are preferred options for managing hypertension in pregnancy [94–97]. Identification of shared oxidative stress mechanisms suggests antioxidant-based therapies (α-lipoic acid, vitamins C/E, N-acetylcysteine) combined with glycemic control may represent a new paradigm for treating high-risk pregnancies [96], although additional studies are needed before they can be recommended. Interventional studies using coenzyme Q10, a key molecule in the electron transport chain, suggest that agents that increase placental antioxidative capacity may be protective against the development of PE [96]. According to ACOG recommendations [98, 99], aspirin is widely recommended for the prevention of PE in high-risk pregnancies, including those with pre-existing diabetes, while magnesium sulfate is the standard medication for treating severe PE and preventing eclamptic seizures. These therapeutic strategies are increasingly supported by underlying molecular mechanisms, including oxidative stress, insulin resistance, endothelial dysfunction and placental dysregulation. While current management strategies for coexisting GDM and PE largely follow ACOG recommendations and rely primarily on insulin therapy, with increasing use of metformin, they do not adequately address the underlying mechanistic heterogeneity of the condition. Notably, the vascular effects of metformin, use of aspirin and emerging antioxidant therapies directly align with these pathways, supporting a shift toward mechanism-based, individualized care. Emerging precision approaches, including genetic and metabolomic stratification and continuous glucose monitoring (CGM)-based profiling, may further refine the treatment of combined GDM and PE [99–102]. Postpartum-Clinical Implications Women who experience pregnancy complications such as PE and GDM remain at a significantly elevated risk of cardiovascular disease during the postpartum period and later in life. The persistence of endothelial dysfunction, chronic inflammation, insulin resistance and adverse cardiometabolic profiles beyond delivery highlights the postpartum phase as a critical transition period in the evolution of cardiovascular risk [89]. Epidemiological evidence demonstrating increased rates of hypertension, ischemic heart disease, heart failure and stroke further reinforces pregnancy as a window that unmasks latent cardiovascular vulnerability [103]. Consequently, strengthening postpartum surveillance and integrating long-term cardiovascular risk reduction strategies into routine postnatal care are essential for improving lifelong cardiovascular outcomes in women. The timing and mode of delivery in pregnancies complicated by PE and GDM depend on the severity of disease, gestational age and maternal fetal status, with early identification and appropriate management being central to optimizing outcomes. Severe PE is associated with a markedly increased risk of maternal and fetal complications, including eclampsia, placental abruption and fetal compromise [104]. Concerns related to intrapartum considerations, delivery decisions and postpartum follow-up in GDM and PE are beyond the scope of the present review. Study Limitations First, this review used a deliberately broad and highly sensitive search strategy to comprehensively capture literature on GDM, PE and related pregnancy complications. However, this approach yielded many irrelevant and duplicate records, increasing the screening burden and reducing review efficiency. Additionally, a substantial proportion of studies were identified through hand-searching, suggesting limitations in database indexing for this topic. Second, substantial heterogeneity was observed across included studies. This was mainly due to variation in diagnostic criteria used for GDM (e.g., IADPSG, WHO 1999, DIPSI, Carpenter & Coustan and national clinical guidelines), wide differences in sample sizes ranging from small clinical cohorts (= 140 participants) to large national datasets (> 2.29 million) and diversity in study designs and population characteristics. These factors may influence reported prevalence estimates and limit direct comparability of findings. Third, geographic variability was another limitation, as studies were conducted across multiple regions, including Australia, India, Greece, Finland, Saudi Arabia and Taiwan. Differences in healthcare systems, screening practices and population risk profiles may have also contributed to variability in reported associations. Furthermore, as this review was conducted as a scoping review rather than a quantitative meta-analysis, findings were interpreted descriptively without statistical pooling or weighting. Another key limitation is that this manuscript does not address the impact of ethnicity on biomarker thresholds. Evidence suggests that metabolic and biomarker profiles in GDM vary across ethnic groups, indicating underlying biological heterogeneity; however, current studies primarily demonstrate differences in biomarker expression rather than establishing ethnicity-specific diagnostic thresholds. Conclusions This review shows that GDM and PE, which are usually treated as two separate conditions despite overlap, may have much in common. The article also highlights the need for further research to determine whether GDM and PE represent different manifestations of a shared underlying etiology or distinct clinical entities that converge at the molecular level. Both GDM and PE are global health concerns, with substantial short- and long-term impacts on both maternal and child health. The co-occurrence of GDM and PE markedly increases the risk of adverse health outcomes for mothers and infants. However, these risks can be mitigated through a multidisciplinary approach encompassing early screening, targeted lifestyle interventions and appropriate pharmacological therapies. Continued research is essential to elucidate the genetic and molecular mechanisms underlying the overlap between GDM and PE, thereby leading to development of effective prevention and management strategies for both conditions. Acknowledgments Medical Writing/Editorial Assistance AI was used only for grammatical checking in Medical writing/Editorial assistance. The authors have reviewed and finalized the current version. Author Contributions Viswanathan Mohan, Lunghar Janeline, Polina Popova and Balaji Bhavadharini conceived the study by collecting relevant articles and performing the literature review. Lunghar Janeline and Thyparambil Aravindakshan Pramodkumar extracted the data using the standardized charting template. Mohan Deepa subsequently cross-checked for accuracy and completeness. Lunghar Janeline worked on the first draft, with edits carried out by Balaji Bhavadharini and Polina Popova. All authors (Lunghar Janeline, Thyparambil Aravindakshan Pramodkumar, Mohan Deepa, Balaji Bhavadharini, Uddhav Chaudhari, Geetanjali Sachdeva, Sadhana Joshi, Haritha Sagili, Anish Keepanasseril, Sadish Kumar Kamalanathan, Polina Popova, Ponnusamy Saravanan, Uma Ram, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Viswanathan Mohan) contributed to writing of the article and read and corrected several versions of the manuscript. All authors have reviewed and finalized the submitted version of the manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published. Funding No funding or sponsorship was received for this study or the publication of this article. Data Availability Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Declarations Conflict of Interest All authors (Lunghar Janeline, Thyparambil Aravindakshan Pramodkumar, Mohan Deepa, Balaji Bhavadharini, Uddhav Chaudhari, Geetanjali Sachdeva, Sadhana Joshi, Haritha Sagili, Anish Keepanasseril, Sadish Kumar Kamalanathan, Polina Popova, Ponnusamy Saravanan, Uma Ram, Ranjit Unnikrishnan, Ranjit Mohan Anjana) declare that they have no conflict of interest to disclose. Viswanathan Mohan is an Editorial Board member of Diabetes Therapy. He was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Ethical Approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.